Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14311983 | 0.98 | ALDH1A1 (0.38) | SLC6A2SLC6A4SLC6A3EPHX1ALDH1A1 | |
| SCHEMBL26894780 | 0.84 | EPHX1 (0.36) | SLC6A2SLC6A4SLC6A3EPHX1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL27903858 | 0.82 | EPHX1 (0.35) | SLC6A2SLC6A4SLC6A3EPHX1ALDH1A1 | |
| SCHEMBL23269569 | 0.82 | EPHX1 (0.38) | SLC6A2SLC6A4SLC6A3EPHX1ALDH1A1 | |
| SCHEMBL13544648 | 0.82 | ALDH1A1 (0.43) | SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL13544944 | 0.82 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL14593819 | 0.82 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL13544642 | 0.82 | ALDH1A1 (0.43) | SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL19781548 | 0.82 | EPHX1 (0.38) | SLC6A2SLC6A4SLC6A3EPHX1ALDH1A1 | |
| SCHEMBL13544941 | 0.82 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2536283-B1 | PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF | TRANSTECH PHARMA LLC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-9045461-B2 | Phenyl-heteroaryl derivatives and methods of use thereof | TRANSTECH PHARMA, LLC (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140206660-A1 | Phenyl-Heteroaryl Derivatives and Methods of Use Thereof | TRANSTECH PHARMA, LLC (US) | 2014-07-24 | — | — | US | disclosed |
| US-8741900-B2 | Phenyl-heteroaryl derivatives and methods of use thereof | TRANSTECH PHARMA, LLC (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130197007-A1 | Phenyl-Heteroaryl Derivatives and Methods of Use Thereof | TRANSTECH PHARMA, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8431575-B2 | Phenyl-heteroaryl derivatives and methods of use thereof | TRANSTECH PHARMA, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| EP-2536283-A1 | PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF | TransTech Pharma, Inc (US) | 2012-12-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206660-A1 | Phenyl-Heteroaryl Derivatives and Methods of Use Thereof | AGER, NOD2, GPBAR1 | SLC6A2 948/4885SLC6A4 1865/4885SLC6A3 1546/4885 |
| US-20130197007-A1 | Phenyl-Heteroaryl Derivatives and Methods of Use Thereof | AGER, PSEN2, PSEN1 | SLC6A2 606/4885SLC6A4 1459/4885SLC6A3 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.